Key result
Novel droplet ADP secretion assay detects single-platelet activation with ~10-fold higher sensitivity than flow cytometry.
Why the study?
New platelet function assays that accurately assess platelet reactivity as a surrogate for thrombosis risk are needed to improve acute myocardial infarction and stroke prevention.
Does the microfluidic Droplet ADP Secretion Assay (DASA) accurately detect and quantify single-platelet ADP secretion across primed, active, and antiplatelet-treated states compared to conventional platelet function assays?
Does the microfluidic Droplet ADP Secretion Assay (DASA) accurately detect and quantify single-platelet ADP secretion across primed, active, and antiplatelet-treated states compared to conventional platelet function assays?
Answers are grounded in this paper and cite their sources.
The Droplet ADP Secretion Assay (DASA) enables highly sensitive, single-platelet quantification of ADP release, uniquely identifying primed platelet states undetected by conventional flow cytometry or aggregometry to potentially guide personalized antiplatelet therapy.
New platelet function assays that provide an accurate assessment of platelet reactivity as a surrogate for thrombosis risk could change the paradigm for acute myocardial infarction and stroke prevention. Considering ADP secretion as a hallmark of platelet activation, we developed a method for encapsulating single platelets with a fluorescent reporter for extracellular ADP in picolitre droplets. The method, termed the Droplet ADP Secretion Assay (DASA), robustly detected dose-dependent ADP secretion responses to agonists. Digital ADP secretion heterogeneity was observed with the major fraction of platelets responding and the remaining fraction being non-responders. Primed platelets had elevated responses to agonists, with increased ADP secretion and an increased fraction of secreting platelets, demonstrating that priming can convert otherwise inactive platelets to a reactive state. Uniquely, the method detected ADP secretion from primed platelets in the absence of agonists. In contrast, primed platelets were not detected by flow cytometry involving CD63 and CD62P endpoints. In a preliminary clinical study, some patients had platelets with a priming-like ADP secretion signature, suggesting treatment with P2Y 12 inhibitors may be warranted. In vitro aspirin and ticagrelor treatments reduced ADP secretion responses to agonists. In summary, DASA offers a novel approach to assess platelet reactivity and holds promise for assessing thrombotic tendency and personalised therapeutics.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2026) studied Thrombosis risk and platelet reactivity (acute myocardial infarction, severe chest infection, fractured neck of femur) (n=19). Droplet ADP Secretion Assay (DASA) vs. Flow cytometry (CD63 and P-selectin), ATP luminescence assay, and light transmission aggregometry was evaluated on Single-platelet extracellular ADP secretion and fraction of responding platelets. The Droplet ADP Secretion Assay (DASA) quantified single-platelet ADP secretion with a 500 nM limit of detection and 10-fold higher sensitivity than P-selectin flow cytometry.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: